Spyre Therapeutics to Present IBD Antibody Data at UEGW 2026

Spyre Therapeutics says it will present first congress clinical data on SPY001, SPY002 and SPY003, along with new preclinical combination data, at UEGW 2026. SKYLINE combination results are expected next year, according to the release.